Cargando…

Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography

Metastatic tumor deposits in bone marrow elicit differential bone responses that vary with the type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can change in morphology due to treatment effects and/or secondary bone remodeling. Hence, morphological imaging is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oprea-Lager, Daniela E., Cysouw, Matthijs C.F., Boellaard, Ronald, Deroose, Christophe M., de Geus-Oei, Lioe-Fee, Lopci, Egesta, Bidaut, Luc, Herrmann, Ken, Fournier, Laure S., Bäuerle, Tobias, deSouza, Nandita M., Lecouvet, Frederic E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640187/ https://www.ncbi.nlm.nih.gov/pubmed/34869009 http://dx.doi.org/10.3389/fonc.2021.772530

Ejemplares similares

Impact of the COVID-19 crisis on imaging in oncological trials
por: Deroose, Christophe M., et al.
Publicado: (2020)

Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group – ESOI Joint Paper
por: Fournier, Laure, et al.
Publicado: (2022)

Standardised lesion segmentation for imaging biomarker quantitation: a consensus recommendation from ESR and EORTC
por: deSouza, Nandita M., et al.
Publicado: (2022)

Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma
por: Poels, Thomas T., et al.
Publicado: (2021)

Correction to: Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers
por: Fournier, Laure, et al.
Publicado: (2021)

Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers
por: Fournier, Laure, et al.
Publicado: (2021)

Editorial: Quantitative Imaging for Clinical Decisions
por: deSouza, Nandita Maria, et al.
Publicado: (2022)

How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation
por: Ambrosini, Valentina, et al.
Publicado: (2023)

Predictive and prognostic value of FDG-PET
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2008)

Editorial on Special Issue “Quantitative PET and SPECT”
por: van Velden, Floris H. P., et al.
Publicado: (2022)

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
por: Luining, Wietske I., et al.
Publicado: (2022)

Fludeoxyglucose positron emission tomography-computed tomography scan showing polyarthritis in a patient with an atypical presentation of Henoch-Schönlein vasculitis without clinical signs of arthritis: a case report
por: Mooij, Christiaan F., et al.
Publicado: (2016)

Methodological considerations in quantification of oncological FDG PET studies
por: Vriens, Dennis, et al.
Publicado: (2009)

Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma
por: Gilles, Rozemarie, et al.
Publicado: (2011)

(18)F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) – A prospective externally validated study
por: Carvalho, Sara, et al.
Publicado: (2018)

Optimization and validation of (18)F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer
por: Luining, Wietske I., et al.
Publicado: (2023)

PET/CT in Patients with Breast Cancer Treated with Immunotherapy
por: Vaz, Sofia C., et al.
Publicado: (2023)

FDG-PET/CT based response-adapted treatment
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2012)

Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas
por: Kleiburg, Fleur, et al.
Publicado: (2023)

Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2020)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Lopci, Egesta
Publicado: (2021)

Meditating on Cancer Management at the Time of Immunotherapy
por: Lopci, Egesta
Publicado: (2022)

Sensitivity of (18)F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2019)

Ablation margin quantification after thermal ablation of malignant liver tumors: How to optimize the procedure? A systematic review of the available evidence
por: Hendriks, Pim, et al.
Publicado: (2023)

The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma
por: Quartuccio, Natale, et al.
Publicado: (2013)

The current role of nuclear medicine in breast cancer
por: Vaz, Sofia C., et al.
Publicado: (2023)

The Value of (18)F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review
por: Bijlstra, Okker D., et al.
Publicado: (2022)

Advances in Lung Cancer Imaging and Therapy
por: Lopci, Egesta, et al.
Publicado: (2021)

Editorial: Response assessment of radioligand therapies
por: Lopci, Egesta, et al.
Publicado: (2022)

FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial
por: de Koster, Elizabeth J., et al.
Publicado: (2022)

Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[(18)F]F PET-CT in Patients With Fibrous Dysplasia/McCune–Albright Syndrome
por: van der Bruggen, Wouter, et al.
Publicado: (2021)

Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients
por: Govaert, Stephanie LA, et al.
Publicado: (2012)

Nanocarriers as a Tool for the Treatment of Colorectal Cancer
por: C. de S. L. Oliveira, Ana Luiza, et al.
Publicado: (2021)

Striatal dopamine synthesis capacity in autism spectrum disorder and its relation with social defeat: an [(18)F]-FDOPA PET/CT study
por: Schalbroeck, Rik, et al.
Publicado: (2021)

EANM practice guideline for quantitative SPECT-CT
por: Dickson, John C., et al.
Publicado: (2022)

Investigating the potential added value of [(18)F]FDG-PET/CT in long COVID patients with persistent symptoms: a proof of concept study
por: Chen, Linda L., et al.
Publicado: (2023)

18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art
por: Castello, Angelo, et al.
Publicado: (2020)

Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?
por: de Koster, Elizabeth J., et al.
Publicado: (2021)

FDG-PET in colorectal cancer
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2006)

Adding the temporal domain to PET radiomic features
por: Noortman, Wyanne A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_la6sr77idrphdrd17tbkkjnf73